EGFR and non-small cell lung carcinoma: Non‐small cell lung cancer (NSCLC) accounts for about 92% of patients with lung cancer3 and in an Asian population 30%–52.4% of patients with NSCLC had EGFR‐activating mutations.4, 5, 6